No Data
No Data
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
Express News | Guardant Health Inc : Leerink Partners Cuts Target Price to $55 From $65
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $60
Guardant Health (NASDAQ:GH) Surges 13% This Week, Taking One-year Gains to 178%
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $60
BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating